Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.40 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.40 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.40 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.40 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.39 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.39 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528153 | 0.97 | TLR7 (0.55) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL29694259 | 0.97 | TLR7 (0.55) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL2402376 | 0.77 | CSNK2A1 (0.44) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL2402419 | 0.75 | PRMT5 (0.46) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL9189866 | 0.73 | ALDH1A1 (0.37) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL29966723 | 0.73 | ALDH1A1 (0.37) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL18499851 | 0.72 | ALDH1A1 (0.39) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL21065257 | 0.71 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL27719811 | 0.71 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| Hydrochloric Acid SCHEMBL5768405 | 0.71 | TLR7 (0.97) | TLR7TLR8ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148232-B2 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1380587-B1 | Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-6809203-B2 | IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6703402-B2 | IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-03-09 | — | — | US | disclosed |
| EP-1380587-A2 | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof | 3M Innovative Properties Company (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677334-B2 | IMMUNOMODULATORS, INDUCE CYTOKINE BIOSYNTHESIS, AND ANTINEOPLASTIC AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-6627640-B2 | Viricides; anticancer agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-30 | — | — | US | disclosed |
| EP-1100802-B1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-06 | — | — | US | disclosed |
| US-6440992-B1 | ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-6323200-B1 | THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. | 3M INNOVATIVE PROPERTIES COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, IL2, IRF3 | GLA 4095/4885GAA 2552/4885ADRA1A 3705/4885 |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | GLA 4303/4885GAA 2664/4885ADRA1A 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.